|
| | Number of patients | Agent used | Dosage | Tolerability | Response | Median time to progression |
|
| Davids et al. [28] |
metastatic disease | Pazopanib | 800 mg daily | Minimal adverse effects; dose reduction after gallstone pancreatitis to 400mg daily | After 2 months: CR of primary lesion, PR of metastatic lesions | 4 months |
|
| Samlowski et al. [29] |
metastatic or unresectable disease | Imatinib | 400 mg daily | Mainly Grade 1-2 toxicities;
3 episodes of Grade 4 toxicities;
Grade 3 toxicities in 3 patients | no CR;
PR: 4% | 1-2 months |
|
| Di Bartolomeo et al. [30] |
metastatic disease (neuroendocrine tumors) | Octreotide | 500 or 1000 micrograms 3 times a day | Carcinoid syndrome and abnormal urinary 5-hydroxy-indoloacetic acid excretion were reported | Median survival time of 22 months (range, 1–32+ months);
PR: 3% | Disease stabilized for at least 6 months (range, 1–32+ months) |
|
| Meier et al. [31] |
locoregional disease | 90Y-DOTATOC;
targeted radiotherapy | 85 mCi | Fatigue was main side effect | PR after 1 week;
CR after 4 weeks | 10 weeks until locoregional relapse |
|
| Fakiha et al. [32] |
clinically locoregional disease | Lanreotide | 15 mg i.m. injection every two weeks | No side effects reported | Clinically CR after 2 months | 7 months until relapse |
|
| Shah et al. [33] |
metastatic or regionally recurrent disease | Oblimersen sodium | 7 mg per kilogram daily | Including Grade 3 and Grade 4 events, for example, lymphopenia, renal failure, cytopenia, and hyperkalemia | No responses; stable disease in 3 patients | PD in 9 patients |
|
